BioCardia price to book ratio BCDA

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 5.2×
10-year median: 18.2×
Against its 10-year history: 8th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.1× to 189×
Peer median: 1.6×

BioCardia's price to book ratio is 5.2× as of Oct 23, 2026.

That is below its ten-year median of 18.2×, lower than on 92% of days in the last ten years.

Over that time it ranged from 3.1× in Nov 2024 to 189× in May 2019.

The median for 7 healthcare stocks of a similar size is 1.6×.

Price to book ratio over time

median 18.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.2×	4.6×	14.7×
2025	5.1×	3.3×	15.9×
2024	4.1×	3.1×	4.1×
2023	15.9×	15.0×	89.1×
2022	27.3×	5.4×	27.3×
2021	7.3×	6.6×	46.5×
2020	31.4×	9.8×	41.0×
2019	14.7×	14.2×	189×
2018	38.2×	14.5×	97.5×
2017	19.5×	18.0×	49.4×
2016	39.0×	3.5×	39.0×
2015	4.0×	3.0×	6.7×
2014	6.2×	4.2×	7.2×
2013	4.7×	3.1×	8.3×
2012	3.0×	3.0×	5.4×
2011	3.6×	2.9×	5.7×

Against its peers

Companies in Healthcare nearest BioCardia's size, closest first, today.

Company	Price to book ratio
BCDABioCardia	5.2×
NEPHNephros	3.2×
ATNMActinium Pharmaceuticals	1.6×
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	1.3×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on BioCardia

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.